Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study Comparing Elranatamab to Drug Combinations for Patients with Relapsed/Refractory Multiple Myeloma After Anti-CD38 Therapy

Fast replyRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a condition known as Relapsed/Refractory Multiple Myeloma, which is a type of blood cancer that has returned or is not responding to treatment. The study aims to compare the effectiveness of a new treatment called Elranatamab against other treatment combinations. These combinations include Elotuzumab, Pomalidomide, and Dexamethasone (EPd); Pomalidomide, Bortezomib, and Dexamethasone (PVd); or Carfilzomib and Dexamethasone (Kd). The purpose of the study is to see how well these treatments work in people who have already received a specific type of therapy known as anti-CD38 directed therapy.

Participants in the study will receive one of these treatments and will be monitored over a period of time to assess the treatment's effectiveness and safety. The study will involve regular check-ups and assessments to track the progress of the disease and any side effects that may occur. The study is designed to provide valuable information on how these treatments compare in terms of helping patients live longer without the disease getting worse.

The trial will continue until the estimated end date in 2029, with recruitment of participants expected to start in 2024. This study is important for understanding better treatment options for people with Relapsed/Refractory Multiple Myeloma and aims to improve the quality of life and outcomes for those affected by this condition.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes reviewing medical history and current health status.

    Eligibility criteria include a prior diagnosis of multiple myeloma and previous treatment with specific therapies.

  2. Step 2

    Treatment assignment

    Participants are assigned to one of two treatment groups: elranatamab monotherapy or a combination therapy group.

    The combination therapy group may include elotuzumab, pomalidomide, dexamethasone (EPd), pomalidomide, bortezomib, dexamethasone (PVd), or carfilzomib, dexamethasone (Kd).

  3. Step 3

    Medication administration

    For those in the elranatamab group, the medication is administered via injection.

    Participants in the combination therapy group receive medications orally or through injection, depending on the specific drugs assigned.

  4. Step 4

    Monitoring and follow-up

    Regular monitoring is conducted to assess the effectiveness of the treatment and any side effects.

    This includes blood tests, imaging studies, and other assessments as needed.

  5. Step 5

    End of treatment evaluation

    At the end of the treatment period, a comprehensive evaluation is performed to determine the overall response to the therapy.

    This includes measuring progression-free survival and overall survival rates.

  6. Step 6

    Long-term follow-up

    Participants may be followed for an extended period to monitor long-term outcomes and any late-emerging effects of the treatment.

    This phase may continue until the estimated end date of the study in January 2029.

Who can join the trial?

8 criteria

  • Participants must be **18 years or older** at the time of screening.
  • Must have a prior diagnosis of **multiple myeloma** (a type of blood cancer) and have received at least 1 but not more than 4 previous treatments for it.
  • Must have had at least 2 cycles of treatment with an **anti-CD38 antibody** (a type of medication) and 2 cycles with **lenalidomide** (another type of medication) in any previous treatment.
  • Must show evidence of the disease getting worse or not responding to the last treatment, as determined by a doctor.
  • Must have a **measurable disease**, which means certain levels of myeloma protein in the blood or urine, or specific levels of free light chains (parts of antibodies) in the blood.
  • Must have a **corrected serum calcium** level of 14 mg/dL or less, or free ionized calcium of 6.5 mg/dL or less. These are measures of calcium in the blood.
  • Must have **adequate bone marrow function**, which means having enough blood cells like white blood cells, platelets, and hemoglobin.
  • Must have an **ECOG performance status** of less than 2, which is a scale used to assess how well a person can perform daily activities.

Who cannot join the trial?

7 criteria

  • Patients who have a different type of cancer other than Relapsed/Refractory Multiple Myeloma cannot participate. Relapsed/Refractory Multiple Myeloma is a type of blood cancer that has returned or is not responding to treatment.
  • Patients who are not within the specified age range for the study cannot participate. The study is open to certain age groups only.
  • Patients who are not able to follow the study procedures or who have conditions that make it unsafe for them to participate cannot join the study.
  • Patients who are pregnant or breastfeeding cannot participate in the study.
  • Patients who have participated in another clinical trial recently may not be eligible to join this study.
  • Patients who have certain medical conditions that could interfere with the study or make it unsafe for them to participate cannot join.
  • Patients who are taking medications that could interfere with the study treatments may not be eligible.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Elranatamab

    is a medication being studied as a single treatment option for patients with relapsed refractory multiple myeloma. It is being tested to see how effective it is compared to other treatment combinations. Elranatamab works by targeting specific proteins on cancer cells, aiming to help the immune system recognize and attack these cells.

  • Elotuzumab

    is part of a combination treatment being compared in the study. It is used alongside other medications to treat multiple myeloma. Elotuzumab helps the immune system find and destroy cancer cells by targeting a specific protein on their surface.

  • Pomalidomide

    is another medication used in combination treatments for multiple myeloma. It works by affecting the immune system and directly attacking cancer cells, helping to slow down or stop their growth.

  • Dexamethasone

    is a steroid used in combination with other cancer treatments. It helps reduce inflammation and can also help kill cancer cells, making other treatments more effective.

  • Bortezomib

    is a medication used in combination therapies for multiple myeloma. It works by interfering with the growth of cancer cells, leading to their death. It is often used when other treatments have not been successful.

  • Carfilzomib

    is another medication used in combination treatments for multiple myeloma. It targets and disrupts the function of certain proteins within cancer cells, leading to their death and helping to control the disease.

What is already known about the treatment

Elranatamab – This medication is administered as an injection and is currently being studied in clinical trials for its effectiveness in treating relapsed or refractory multiple myeloma, a type of blood cancer. It is not yet widely available in medical practice, as it is still under investigation. Elranatamab works by targeting specific proteins on cancer cells, helping the immune system to recognize and destroy these cells. It is classified as a monoclonal antibody, which is a type of targeted cancer therapy.

Investigated diseases

Relapsed/Refractory Multiple Myeloma – This is a type of blood cancer that affects plasma cells, which are a type of white blood cell found in the bone marrow. In relapsed or refractory cases, the disease has returned after treatment or does not respond to standard therapies. It typically progresses by causing damage to bones, kidneys, and the immune system. Patients may experience symptoms such as bone pain, fatigue, and frequent infections. The disease can lead to anemia and high levels of calcium in the blood. Over time, it can become more challenging to manage as it becomes resistant to treatments.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-507871-23-00Protocol codeC1071032Estimated enrolment473 patientsSponsorPfizer Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).